These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10964992)

  • 1. Highlights in ovarian cancer.
    Seiden M
    Oncologist; 2000; 5(4):267-73. PubMed ID: 10964992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
    Stewart L;
    Cochrane Database Syst Rev; 2000; (2):CD001418. PubMed ID: 10796788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of advanced ovarian cancer.
    McGuire WP; Ozols RF
    Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
    Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
    Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
    Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New aspects by the therapy of ovarian cancer--What changes after the ASCO-Meeting 2001].
    Costa SD; von Minckwitz G; Wernicke K; Kaufmann M
    Zentralbl Gynakol; 2002 Feb; 124(2):96-103. PubMed ID: 11935494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
    Monk BJ; Coleman RL
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
    Coleman RL
    Oncologist; 2002; 7 Suppl 5():46-55. PubMed ID: 12324633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
    Thigpen JT
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy for epithelial ovarian carcinoma.
    Christian MC; Trimble EL
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer.
    Seiden MV
    Oncologist; 2001; 6(4):327-32. PubMed ID: 11524550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
    Markman M
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
    Scarfone G
    Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.